Skip to main content

Kuvatris Therapeutics, Inc.

PXMDDelisted Aug 8, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001811623

Kuvatris Therapeutics, Inc. was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Mar 14, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.

13F holders, Q4 2022

Institutional positions in Kuvatris Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
8
+2 vs. Q3 2022
Shares held
86.6K
+31.3K (+56.6%) vs. Q3 2022
Total value
$176.0K
+$21.0K (+13.6%) vs. Q3 2022
New holders
5
2 more added
Sold out
3
1 more reduced

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting PXMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 8 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 6 institutionsQ4 2022: 8 institutionsQ1 2023: 10 institutionsQ2 2023: 8 institutionsQ3 2023: 13 institutionsQ4 2023: 9 institutionsQ1 2024: 8 institutionsQ2 2024: 1 institutionQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ4 2022: $176.0K
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $155.0KQ4 2022: $176.0KQ1 2023: $307.6KQ2 2023: $165.3KQ3 2023: $85.8KQ4 2023: $84.2KQ1 2024: $64.7KQ2 2024: $12Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding PXMD and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20241$12
Q1 20248$64.7K
Q4 20239$84.2K
Q3 202313$85.8K
Q2 20238$165.3K
Q1 202310$307.6K
Q4 20228$176.0K
Q3 20226$155.0K
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Kuvatris Therapeutics, Inc.; share changes are against Q3 2022.

Institutions holding PXMD in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
UBS Group AG33,404$67.8K0.00%+27,198+438.3%Added
State Street Corp21,900$44.5K0.00%+21,900New
Bank of America Corp14,546$29.5K0.00%+14,546New
Virtu Financial LLC10,123$21.0K0.00%−3,985−28.2%Reduced
Tower Research Capital LLC (TRC)5,457$11.0K0.00%+3,589+192.1%Added
Advisor Group Holdings, Inc.1,000$2.00K0.00%+1,000New
Barclays PLC100$2040.00%+100New
Wells Fargo & Company22$450.00%+22New
Bank of Montreal0$00.00%−15,000−100.0%Sold out
Jane Street Group, LLC0$00.00%−18,025−100.0%Sold out
Royal Bank of Canada0$00.00%−68−100.0%Sold out